- Home
- INTS vs YCBD Comparison
INTS vs YCBD Comparison
Compare INTS & YCBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- YCBD
- Stock Information
- Founded
- INTS 2012
- YCBD 2015
- Country
- INTS United States
- YCBD United States
- Employees
- INTS N/A
- YCBD N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- YCBD Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- YCBD Health Care
- Exchange
- INTS Nasdaq
- YCBD Nasdaq
- Market Cap
- INTS 8.4M
- YCBD 7.8M
- IPO Year
- INTS 2023
- YCBD N/A
- Fundamental
- Price
- INTS $0.30
- YCBD $0.66
- Analyst Decision
- INTS Strong Buy
- YCBD Strong Buy
- Analyst Count
- INTS 4
- YCBD 1
- Target Price
- INTS $4.50
- YCBD $2.00
- AVG Volume (30 Days)
- INTS 5.8M
- YCBD 124.3K
- Earning Date
- INTS 08-07-2025
- YCBD 08-14-2025
- Dividend Yield
- INTS N/A
- YCBD N/A
- EPS Growth
- INTS N/A
- YCBD N/A
- EPS
- INTS N/A
- YCBD N/A
- Revenue
- INTS N/A
- YCBD $19,026,064.00
- Revenue This Year
- INTS N/A
- YCBD $7.67
- Revenue Next Year
- INTS N/A
- YCBD $10.00
- P/E Ratio
- INTS N/A
- YCBD N/A
- Revenue Growth
- INTS N/A
- YCBD N/A
- 52 Week Low
- INTS $0.19
- YCBD $0.59
- 52 Week High
- INTS $4.35
- YCBD $6.54
- Technical
- Relative Strength Index (RSI)
- INTS 49.95
- YCBD 33.49
- Support Level
- INTS $0.28
- YCBD $0.59
- Resistance Level
- INTS $0.32
- YCBD $0.73
- Average True Range (ATR)
- INTS 0.03
- YCBD 0.09
- MACD
- INTS 0.01
- YCBD -0.02
- Stochastic Oscillator
- INTS 78.80
- YCBD 17.31
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.